3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Status
Recruiting
2
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
CNS
1
Conditions
Breast Neoplasms
3
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Fulvestrant
65
Letrozole
55
Paclitaxel
54
pembrolizumab
42
Trastuzumab
42
ribociclib
39
Specimen Handling
36
palbociclib
35
Capecitabine
35
Carboplatin
34
Anastrozole
34
Tamoxifen
32
exemestane
31
abemaciclib
31
pertuzumab
29
Cyclophosphamide
27
Magnetic Resonance Spectroscopy
26
trastuzumab deruxtecan
24
Radiotherapy
22
Surveys and Questionnaires
20
Blood Specimen Collection
20
olaparib
18
Biopsy
18
Standard of Care
17
Docetaxel
17
Taxes
15
130-nm albumin-bound paclitaxel
15
eribulin
14
Methods
14
Mastectomy, Segmental
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
RAD1901
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled
NCT07198724
2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2
Recruiting
65 enrolled
NCT05963997
2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2
Completed
49 enrolled